Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551039 | 0.96 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1HPGDHIF1ASSTR5 | |
| SCHEMBL3555911 | 0.91 | FPR2 (0.41) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL3549061 | 0.91 | PDE4B (0.41) | SMN1; SMN2ALDH1A1HPGDPDE4APDE4B | |
| SCHEMBL3549573 | 0.90 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL3676934 | 0.89 | SSTR5 (0.39) | SMN1; SMN2SSTR5S1PR1FPR2KDM4E | |
| SCHEMBL3674351 | 0.89 | SSTR5 (0.39) | SMN1; SMN2SSTR5S1PR1FPR2KDM4E | |
| SCHEMBL3546345 | 0.88 | FPR2 (0.39) | ALDH1A1SSTR5PDE4APDE4BPDE4C | |
| SCHEMBL3673308 | 0.88 | PARP1 (0.38) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3677395 | 0.88 | SSTR5 (0.39) | ALDH1A1HPGDHIF1ASSTR5S1PR1 | |
| SCHEMBL3671921 | 0.88 | SSTR5 (0.39) | SMN1; SMN2ALDH1A1HPGDSSTR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | claimed |
| EP-1948167-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2007045980-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | claimed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | claimed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| EP-1948167-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045980-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | SMN1; SMN2 2909/4885ALDH1A1 2460/4885HPGD 399/4885 |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | PDE7A, PDE4A, PDE4B | SMN1; SMN2 4708/4885ALDH1A1 718/4885HPGD 215/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | SMN1; SMN2 2900/4885ALDH1A1 2681/4885HPGD 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.